Article info
Review
Antithrombotic treatment and intracerebral haemorrhage: between Scylla and Charybdis
- Correspondence to Dr Jeannette Hofmeijer, neurologist, Department of Neurology, Rijnstate Hospital, Wagnerlaan 55, Arnhem 6815 AD, The Netherlands; jhofmeijer{at}rijnstate.nl
Citation
Antithrombotic treatment and intracerebral haemorrhage: between Scylla and Charybdis
Publication history
- Accepted March 22, 2015
- First published April 28, 2015.
Online issue publication
July 14, 2015
Article Versions
- Previous version (28 April 2015).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions
Other content recommended for you
- Oral anticoagulation therapy use in patients with atrial fibrillation after the introduction of non-vitamin K antagonist oral anticoagulants: findings from the French healthcare databases, 2011–2016
- Non-vitamin K antagonist oral anticoagulants and major bleeding-related fatality in patients with atrial fibrillation and venous thromboembolism: a systematic review and meta-analysis
- Non-vitamin K antagonist oral anticoagulants (NOACs): clinical evidence and therapeutic considerations
- Non-vitamin K antagonist oral anticoagulants (NOACs) for the management of venous thromboembolism
- The increasing impact of cerebral amyloid angiopathy: essential new insights for clinical practice
- Comparative effectiveness of oral anticoagulants in everyday practice
- Efficacy and safety of non-vitamin K antagonist oral anticoagulants compared with warfarin in patients with atrial fibrillation
- Non-vitamin K antagonist oral anticoagulants in adults with a Fontan circulation: are they safe
- Medical management of intracerebral haemorrhage
- Safety of switching from vitamin K antagonist to non-vitamin K antagonist oral anticoagulant in frail elderly with atrial fibrillation: rationale and design of the FRAIL-AF randomised controlled trial